Article Details

AstraZeneca, Alteogen Enter License Agreement for Subcutaneous Formulations of Oncology Assets

Retrieved on: 2025-03-17 16:10:00

Tags for this article:

Click the tags to see associated articles and topics

AstraZeneca, Alteogen Enter License Agreement for Subcutaneous Formulations of Oncology Assets. View article details on hiswai:

Excerpt

AstraZeneca and Alteogen Inc. have entered into an exclusive license agreement for ALT-B4, a novel hyaluronidase utilizing Hybrozyme platform ...

Article found on: www.contractpharma.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up